Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan

[1]  David W. Johnson,et al.  HMG CoA reductase inhibitors (statins) for dialysis patients. , 2013, The Cochrane database of systematic reviews.

[2]  Andrew Davenport,et al.  Reimbursement of dialysis: a comparison of seven countries. , 2012, Journal of the American Society of Nephrology : JASN.

[3]  S. Hedayati,et al.  Renal replacement therapy in the elderly population. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[4]  V. Tesar,et al.  EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: A prospective observational cohort study. , 2012, Clinical biochemistry.

[5]  T. Hasegawa,et al.  Overview of Regular Dialysis Treatment in Japan (as of 31 December 2009) , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  T. Chang.  Systolic Blood Pressure and Mortality in Patients on Hemodialysis , 2011, Current hypertension reports.

[7]  Y. Mori,et al.  Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[8]  Gene Kim,et al.  S100A12 in Vascular Smooth Muscle Accelerates Vascular Calcification in Apolipoprotein E–Null Mice by Activating an Osteogenic Gene Regulatory Program , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[9]  A. Nakashima,et al.  Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[10]  K. Iseki,et al.  2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease , 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[11]  J. Himmelfarb.  Innovation in the Treatment of Uremia: Proceedings from the Cleveland Clinic Workshop: Uremic Toxicity, Oxidative Stress, and Hemodialysis as Renal Replacement Therapy , 2009, Seminars in dialysis.

[12]  Frits R Rosendaal,et al.  Cardiovascular and noncardiovascular mortality among patients starting dialysis. , 2009, JAMA.

[13]  M. Solomon,et al.  The relationship between laboratory‐based outcome measures and mortality in end‐stage renal disease: A systematic review , 2009, Hemodialysis international. International Symposium on Home Hemodialysis.

[14]  H. Freeze,et al.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. , 2009, Neoplasia.

[15]  Jens Pietzsch,et al.  Human S100A12: a novel key player in inflammation? , 2009, Amino Acids.

[16]  CaCO,et al.  Clinical Practice Guideline for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[17]  K. Wakai,et al.  Overview of Regular Dialysis Treatment in Japan as of 31 December 2006 , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[18]  Y. Mori,et al.  Increased Plasma S100A12 (EN-RAGE) Levels in Hemodialysis Patients with Atherosclerosis , 2008, American Journal of Nephrology.

[19]  K. Wakai,et al.  Overview of Regular Dialysis Treatment in Japan (as of 31 December 2005) , 2007, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[20]  S. Fukuhara,et al.  The organization and financing of end-stage renal disease treatment in Japan , 2007, International Journal of Health Care Finance and Economics.

[21]  M. Bianchi.  DAMPs, PAMPs and alarmins: all we need to know about danger , 2007, Journal of leukocyte biology.

[22]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[23]  Anne Dawnay,et al.  Profound mishandling of protein glycation degradation products in uremia and dialysis. , 2005, Journal of the American Society of Nephrology : JASN.

[24]  O Fitzgerald,et al.  Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. , 2003, Rheumatology.

[25]  D. Foell,et al.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease , 2003, Gut.

[26]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[27]  D. Foell,et al.  S100A12 (EN-RAGE) in monitoring Kawasaki disease , 2003, The Lancet.

[28]  Yu-ling,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[29]  R. Donato,et al.  S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. , 2001, The international journal of biochemistry & cell biology.

[30]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[31]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[32]  F. Port,et al.  Five-year survival for end-stage renal disease patients in the United States, Europe, and Japan, 1982 to 1987. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  C. Metz.  Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.

[34]  B. Scribner,et al.  The technique of continous hemodialysis. , 1960, Transactions - American Society for Artificial Internal Organs.

[35]  David W. Johnson,et al.  HMG CoA reductase inhibitors (statins) for dialysis patients. , 2009, The Cochrane database of systematic reviews.

[36]  M. Zanetti,et al.  Journal of Translational Medicine BioMed Central , 2006 .

[37]  Ping-yan Chen,et al.  J Am Soc Nephrol 15: 1889–1896, 2004 Enhanced Expression of Receptor for Advanced Glycation End Products in Chronic Kidney Disease , 2003 .